Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report
- PMID: 31914067
- PMCID: PMC6959891
- DOI: 10.1097/MD.0000000000018688
Anastrozole-induced pulmonary cryptococcosis in a patient with early breast cancer: A case report
Abstract
Introduction: Estrogen is a key factor in breast cancer carcinogenesis, and reductions in its synthesis can decrease breast cancer risk. Anastrozole can reduce plasma estrogen levels by inhibiting the enzyme aromatase, and is approved for adjuvant treatment of breast cancer. We report a case of pulmonary cryptococcosis in a patient who was treated with anastrozole for an early-stage tumor. This case is of special interest because the patient achieved a better curative effect after the administration of anastrozole was discontinued.
Patient concerns: A 61-year-old woman was found to have multiple pulmonary nodules on chest computed tomography (CT) after being treated for 5 months with anastrozole as an adjuvant breast cancer therapy. A biopsy of the largest lesion of the right lung showed cryptococcus fungal bodies with granulomatous inflammation, so the patient was diagnosed with pulmonary cryptococcosis. She was treated with fluconazole (400 mg/day) for 1 month, but a follow-up CT scan of chest showed no improvement.
Diagnosis: Pulmonary cryptococcosis.
Interventions: Because the pulmonary cryptococcosis was not improving, the administration of anastrozole was discontinued. Fluconazole was continued.
Outcomes: The pulmonary lesions diminished in size 2 months after discontinuing anastrozole. The patient continued taking fluconazole for a total of 6 months without re-administration of anastrozole, and the lesions of pulmonary cryptococcosis almost disappeared.
Conclusion: This case of pulmonary cryptococcosis may have been induced by a decrease in estrogen level caused by the aromatase inhibitor, anastrozole. Treatment of pulmonary cryptococcosis with concurrent anastrozole use may be ineffective, and it may be better to discontinue the aromatase inhibitor.
Conflict of interest statement
The authors have no conflicts of interests to disclose.
Figures


Similar articles
-
[Case of pulmonary cryptococcosis which developed in a patient receiving abatacept therapy for rheumatoid arthritis].Nihon Kokyuki Gakkai Zasshi. 2010 Dec;48(12):980-4. Nihon Kokyuki Gakkai Zasshi. 2010. PMID: 21226309 Japanese.
-
Pulmonary cryptococcosis coexisting with central type lung cancer in an immuocompetent patient: a case report and literature review.BMC Pulm Med. 2020 Jun 5;20(1):161. doi: 10.1186/s12890-020-01200-z. BMC Pulm Med. 2020. PMID: 32503511 Free PMC article. Review.
-
[A case of secondary pulmonary cryptococcosis complicating diabetes mellitus].Nihon Kokyuki Gakkai Zasshi. 2004 Mar;42(3):272-6. Nihon Kokyuki Gakkai Zasshi. 2004. PMID: 15069786 Japanese.
-
RAPIDLY PROGRESSIVE PULMONARY CRYPTOCOCCOSIS WITH CAVITATION IN AN IMMUNOCOMPETENT WOMAN: A CASE REPORT AND LITERATURE REVIEW.Southeast Asian J Trop Med Public Health. 2017 Jan;48(1):179-83. Southeast Asian J Trop Med Public Health. 2017. PMID: 29644837 Review.
-
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.Respir Med Case Rep. 2017 Jul 4;22:87-90. doi: 10.1016/j.rmcr.2017.06.015. eCollection 2017. Respir Med Case Rep. 2017. PMID: 28721333 Free PMC article.
Cited by
-
Non-self glycan structures as possible modulators of cancer progression: would polysaccharides from Cryptococcus spp. impact this phenomenon?Braz J Microbiol. 2023 Jun;54(2):907-919. doi: 10.1007/s42770-023-00936-0. Epub 2023 Feb 25. Braz J Microbiol. 2023. PMID: 36840821 Free PMC article. Review.
References
-
- Iwase H. Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 2008;15:278–90. - PubMed
-
- Moscetti L, Agnese FM, Sperduti I, et al. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment? Tumori 2015;101:469–73. - PubMed
-
- Nadkarni S, McArthur S. Oestrogen and immunomodulation: new mechanisms that impact on peripheral and central immunity. Curr Opin Pharmacol 2013;13:576–81. - PubMed
-
- Mohr JA, Long H, Mckown BA, et al. In vitro susceptibility of Cryptococcus neoformans to steroids. Sabouraudia 1972;10:171–2. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical